Drug Shortage Report for MIDAZOLAM INJECTION
| Report ID | 179688 |
| Drug Identification Number | 02242905 |
| Brand name | MIDAZOLAM INJECTION |
| Common or Proper name | MIDAZOLAM INJECTION |
| Company Name | FRESENIUS KABI CANADA LTD |
| Market Status | MARKETED |
| Active Ingredient(s) | MIDAZOLAM |
| Strength(s) | 5MG |
| Dosage form(s) | LIQUID |
| Route of administration | INTRAVENOUS INTRAMUSCULAR INTRAVENOUS INTRAMUSCULAR |
| Packaging size | 2 mL |
| ATC code | N05CD |
| ATC description | HYPNOTICS AND SEDATIVES |
| Reason for shortage | Disruption of the manufacture of the drug. |
| Anticipated start date | 2023-01-15 |
| Actual start date | 2023-01-15 |
| Estimated end date | 2023-04-01 |
| Actual end date | 2023-04-01 |
| Shortage status | Resolved |
| Updated date | 2023-04-03 |
| Company comments | Fresenius Kabi Canada regrets to advise that due to a production delay, we will be encountering a supply interruption on our Midazolam Injection 5 mg/mL MD Vial 2 mL effective January 15, 2023 until April 1, 2023. During this time, our Midazolam Injection 1 mg/mL MD Vial 10 mL and 5 mg/mL MD Vial 1 mL will be available for substitution. |
| Health Canada comments | |
| Tier 3 Status | No |
| Contact Address | 165 GALAXY BLVD, SUITE 100 TORONTO, ONTARIO CANADA M9W 0C8 |
| Company contact information |
Version History
Click on "Compare" below to view the full report history and compare to other versions.
| Version Number | Date Updated | Language | |
|---|---|---|---|
| v7 | 2023-04-03 | French | Compare |
| v6 | 2023-04-03 | English | Compare |
| v5 | 2023-02-09 | French | Compare |
| v4 | 2023-02-09 | English | Compare |
| v3 | 2023-01-16 | English | Compare |
| v2 | 2023-01-02 | French | Compare |
| v1 | 2023-01-02 | English | Compare |
Showing 1 to 7 of 7